Efficacy and safety of reduced thromboprophylaxis with low molecular weight heparin for hepatocellular carcinoma after conversion therapy.

BMC Gastroenterol · 2025 · PMC12369263 · PMID 40835902

Europe PMC DOI

hedged sentence

0.0830

closest p · 1.7× alpha

0.0830

boldest claim

The sentences

showed a trendP = 0.083so close (0.05 < p ≤ 0.1)

Univariate analysis showed a trend toward reduced VTE risk with reduced LMWH prophylaxis (OR = 0.31, 95% CI: 0.08–1.16, P = 0.083), which remained non-significant after multivariate adjustment for ALBI score, PT, cirrhosis, major hepatectomy, and other covariates (adjusted OR = 0.33, 95% CI: 0.09–1.21, P = 0.098).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.